Hazel Yetiskin

Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model

A. Ozdarendeli, A. Kalkan, Shaikh Terkis Islam Pavel, 2020, PLoS neglected tropical diseases.

Development of an Inactivated Vaccine against SARS CoV-2

A. Ozdarendeli, M. Uygut, Öznur İnan, 2021, Vaccines.

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

Darren L. Smith, Evelien M. Adriaenssens, Gemma L. Kay, 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey

Can Holyavkin, I. Çelik, A. Ozdarendeli, 2020, PloS one.

Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants

T. Mamedov, D. Yuksel, A. Ozdarendeli, 2022, bioRxiv.

Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials

A. Kara, A. Ozdarendeli, Gamze Kalin Unuvar, 2022, Vaccine.

Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

F. Şahin, M. Çetin, Ş. Tekin, 2022, Frontiers in Immunology.

Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19

T. Mamedov, D. Yuksel, A. Ozdarendeli, 2021, Vaccines.

Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice

T. Mamedov, D. Yuksel, A. Ozdarendeli, 2021, Viruses.

Safety immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: interim results from randomised, dou-ble-blind, placebo-controlled phase 1 and 2 trials

A. Ozdarendeli, Gamze Kalin Unuvar, M. Mazıcıoğlu, 2022 .

Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

A. Ozdarendeli, M. Mazıcıoğlu, M. Uygut, 2024, Vaccines.